These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30837157)

  • 1. [5-FU: At last!].
    Robert J
    Bull Cancer; 2019 Mar; 106(3):173-174. PubMed ID: 30837157
    [No Abstract]   [Full Text] [Related]  

  • 2. Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency.
    Saif MW; Diasio RB
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):151-6. PubMed ID: 27278667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature.
    Zurayk M; Keung YK; Yu D; Hu EH
    J Oncol Pharm Pract; 2019 Jan; 25(1):234-238. PubMed ID: 28950804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
    Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
    Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early-Onset 5-Fluorouracil Toxicity in a Patient Negative for Dihydropyrimidine Dehydrogenase Mutations: The Clinical Course of Reversal with Uridine Triacetate.
    Vaudo CE; Gil B; Galuski K; Zarwan C; Nugent FW
    Pharmacotherapy; 2016 Nov; 36(11):e178-e182. PubMed ID: 27716991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prompt treatment with uridine triacetate improves survival and reduces toxicity due to fluorouracil and capecitabine overdose or dihydropyrimidine dehydrogenase deficiency.
    Garcia RAG; Saydoff JA; Bamat MK; von Borstel RW
    Toxicol Appl Pharmacol; 2018 Aug; 353():67-73. PubMed ID: 29908244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.
    Ma WW; Saif MW; El-Rayes BF; Fakih MG; Cartwright TH; Posey JA; King TR; von Borstel RW; Bamat MK
    Cancer; 2017 Jan; 123(2):345-356. PubMed ID: 27622829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases.
    Cordier PY; Nau A; Ciccolini J; Oliver M; Mercier C; Lacarelle B; Peytel E
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):823-6. PubMed ID: 21553285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Severe capecitabine-associated toxicity in a patient carrying a mutation in the dihydropyrimidine dehydrogenase gen].
    González-Haba E
    Farm Hosp; 2012; 36(6):554-5. PubMed ID: 23461455
    [No Abstract]   [Full Text] [Related]  

  • 10. Detection of complete dihydropyrimidine dehydrogenase deficiency in a Tunisian family using a simple phenotypic test.
    Mani A; Nouira M; Ahmed SB; Saguem S
    Indian J Pharmacol; 2013; 45(4):414-5. PubMed ID: 24014927
    [No Abstract]   [Full Text] [Related]  

  • 11. [Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].
    Loriot MA; Masskouri F; Carni P; Le Malicot K; Seitz JF; Michel P; Legoux JL; Bouché O; André T; Faroux R; Delaloge S; Malka D; Guigay J; Thariat J; Thomas F; Barin-Le-Guellec C; Ciccolini J; Boyer JC; Étienne-Grimaldi MC
    Bull Cancer; 2019 Sep; 106(9):759-775. PubMed ID: 31253356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (13)C-uracil breath test to predict 5-fluorouracil toxicity in gastrointestinal cancer patients.
    Cunha-Junior GF; De Marco L; Bastos-Rodrigues L; Bolina MB; Martins FL; Pianetti GA; Cesar IC; Coelho LG
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1273-82. PubMed ID: 24101147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current insights into the impact of dihydropyrimidine dehydrogenase deficiency in patients receiving treatment with 5-fluorouracil.
    Diasio RB
    Clin Adv Hematol Oncol; 2016 Jul; 14(7):510-2. PubMed ID: 27379945
    [No Abstract]   [Full Text] [Related]  

  • 14. Fluoropyrimidine-induced toxicity and DPD deficiency.. A case report of early onset, lethal capecitabine-induced toxicity and mini review of the literature. Uridine triacetate: Efficacy and safety as an antidote. Is it accessible outside USA?
    Lampropoulou DI; Laschos K; Amylidi AL; Angelaki A; Soupos N; Boumpoucheropoulos S; Papadopoulou E; Nanou E; Zidianakis V; Nasioulas G; Fildissis G; Aravantinos G
    J Oncol Pharm Pract; 2020 Apr; 26(3):747-753. PubMed ID: 31382864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In brief: uridine triacetate (Vistogard) for fluorouracil overdose.
    Med Lett Drugs Ther; 2016 Jul; 58(1498):90. PubMed ID: 27348145
    [No Abstract]   [Full Text] [Related]  

  • 16. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
    Meulendijks D; Henricks LM; Jacobs BAW; Aliev A; Deenen MJ; de Vries N; Rosing H; van Werkhoven E; de Boer A; Beijnen JH; Mandigers CMPW; Soesan M; Cats A; Schellens JHM
    Br J Cancer; 2017 May; 116(11):1415-1424. PubMed ID: 28427087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lethal toxicity after 5-fluorouracil chemotherapy and its possible relationship to dihydropyrimidine dehydrogenase deficiency: a case report and review of the literature.
    Díaz R; Segura A; Aparicio J; Calderero V; Guerrero A; Pellín L
    J Chemother; 2004 Dec; 16(6):599-603. PubMed ID: 15700854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient.
    Blasco H; Boisdron-Celle M; Bougnoux P; Calais G; Tournamille JF; Ciccolini J; Autret-Leca E; Le Guellec C
    Br J Clin Pharmacol; 2008 Jun; 65(6):966-70. PubMed ID: 18294332
    [No Abstract]   [Full Text] [Related]  

  • 19. Determination of 5-fluorouracil and dihydrofluorouracil levels by using a liquid chromatography-tandem mass spectrometry method for evaluation of dihydropyrimidine dehydrogenase enzyme activity.
    Serdar MA; Sertoğlu E; Uyanık M; Tapan S; Akın O; Cihan M
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):525-9. PubMed ID: 21107571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A bilateral cicatricial ectropion and bilateral upper lid shortening caused by 5-fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency.
    Obi EE; McDonald A; Kemp E
    Cutan Ocul Toxicol; 2011 Jun; 30(2):157-9. PubMed ID: 21077799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.